In colorectal carcinoma models, Probody-engineered EGFR/CD3 bispecific antibodies (e.g., CI107) demonstrated a marked reduction in toxicity while maintaining therapeutic efficacy (127). This evidence concerns the gene EGFR and colorectal carcinoma.